Systemic Treatment of Fabry Disease Using a Novel AAV9 Vector Expressing α-Galactosidase A
Fabry disease is a rare X-linked disorder affecting α-galactosidase A, a rate-limiting enzyme in lysosomal catabolism of glycosphingolipids. Current treatments present important limitations, such as low half-life and limited distribution, which gene therapy can overcome. The aim of this work was to...
Main Authors: | Maria Grazia Biferi, Mathilde Cohen-Tannoudji, Andrea García-Silva, Olga Souto-Rodríguez, Irene Viéitez-González, Beatriz San-Millán-Tejado, Andrea Fernández-Carrera, Tania Pérez-Márquez, Susana Teijeira-Bautista, Soraya Barrera, Vanesa Domínguez, Thibaut Marais, África González-Fernández, Martine Barkats, Saida Ortolano |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-03-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050120302205 |
Similar Items
-
Systemic AArh10 provides higher transgene expression than AAV9, in the brain and the spinal cord of neonatal mice
by: Yannick eTanguy, et al.
Published: (2015-07-01) -
α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice
by: Julen Rodríguez-Castejón, et al.
Published: (2021-05-01) -
Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors
by: Qizhao Wang, et al.
Published: (2017-03-01) -
Accurate Quantification of AAV Vector Genomes by Quantitative PCR
by: Cristina Martinez-Fernandez de la Camara, et al.
Published: (2021-04-01) -
Biochemical and Structural studies of AAV-2 Rep68-AAVS1 complex assembly
by: Bishop, Clayton
Published: (2014)